Table 3.
Baseline disease characteristics of study participants with MS.
| Characteristica | Participants with MS (self-referred; N=359) | Participants with MS (clinic referred; N=136) |
|
|
| MSb diagnosis | ||||
|
|
Relapsing–remitting | 300 (83.6) | 123 (90.4) |
|
|
|
Primary progressive | 34 (9.5) | 6 (4.4) |
|
|
|
Secondary progressive | 25 (7.0) | 5 (3.7) |
|
|
|
Not sure | 0 (0.0) | 2 (1.5) |
|
| Current DMTc | ||||
|
|
Infusion | 116 (32.3) | 64 (47.1) |
|
|
|
Injection | 83 (23.1) | 24 (17.6) |
|
|
|
Oral | 114 (31.8) | 40 (29.4) |
|
|
|
None | 46 (12.8) | 6 (4.4) |
|
|
|
Missing | 0 (0.0) | 2 (1.5) |
|
| MS family history | ||||
|
|
Yes | 77 (21.4) | 23 (16.9) |
|
|
|
No | 251 (69.9) | 104 (76.5) |
|
|
|
Not sure | 31 (8.6) | 9 (6.6) |
|
| Overall physical abilityd | ||||
|
|
Normal | 101 (28.1) | 52 (38.2) |
|
|
|
Gait disability | 85 (23.7) | 24 (17.6) |
|
|
|
Mild disability | 104 (29.0) | 38 (27.9) |
|
|
|
Moderate disability | 69 (19.2) | 20 (14.7) |
|
|
|
Missing | 0 (0.0) | 2 (1.5) |
|
| Duration of disease | ||||
|
|
Years since diagnosis, mean (SD) | 11.14 (8.86) | 14.29 (8.89) |
|
| Duration of treatment | ||||
|
|
Years since first DMT, mean (SD) | 10.09 (7.97) | 13.07 (7.92) |
|
aAll data shown are n (%), unless otherwise stated.
bMS: multiple sclerosis.
cDMT: disease-modifying therapy.
dBased on truncated 4-point Patient Determined Disease Steps scale.